CO

The Cooper Companies, Inc.

COOHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$4.09B
+5.1% YoY
Net Income
$374.9M
-4.4% YoY
EBITDA
$1.04B
-2.6% YoY
Free Cash Flow
$424.3M

Scan Results

Daily timeframe
10 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 20.3, below 30, stock may be oversold
Sep 2CONFIRMED RSI OversoldRSI 16.9, below 30, stock may be oversold
About The Cooper Companies, Inc.

Part of the healthcare sector, The Cooper Companies, Inc. (COO) is listed under Medical Instruments & Supplies. The $13.20B market capitalization puts COO squarely in large-cap range for its industry. The company operates in two segments, CooperVision and CooperSurgical.

Where COO stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, COO finished 2.05% below its 150-day moving average ($71.19) and 5.00% below its 200-day moving average ($73.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is COO overbought or oversold?

At the September 3, 2026 close, COO's RSI(14) was 20.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$13.20B
P/E (TTM)57.36
Fwd P/E13.55
EPS$1.18
Beta0.82
52W Change+2.0%
ROE2.9%
Analysis

The Cooper Companies, Inc. carries $2.73B in total debt against $138.8M in cash reserves — debt is roughly 19.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $424.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 2.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.31B (2022) to $4.09B (2025), reflecting a 24% increase over the period.

Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. At over 50x earnings, COO carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence The Cooper Companies, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms